Two of Europe's leading pharma companies, Sanofi and Bayer AG, have refreshed their executive line-up with personnel from the other company, in moves which will see a new head of pharmaceuticals at Germany's Bayer, and changes to the global business units (GBUs) of France's Sanofi that will produce a large primary care GBU and a new GBU focused on China and emerging markets.
The changes follow disappointing starts to 2018 for both companies; uninspiring financials and manufacturing issues have affected Bayer Also see...





